Paralytic ileus is a temporary arrest of intestinal peristalsis. We report on two patients with breast cancer who developed paralytic ileus following treatment with capecitabine. The pathophysiology of this disorder and its possible connection to capecitabine are described with the aim of promoting the early recognition of the clinical picture so that unnecessary surgery can be avoided.
WalkoC.M., LindleyC.: Capecitabine: a review. Clin Ther, 27: 23–44, 2005.
2.
HoffP.H., AnsariR., BatistG., CoxJ., KochaW., KupermincM., MarounJ., WaldeD., WeaverC., HarrisonE., BurgerH.U., OsterwalderB., WongA.O., WongR.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol, 19: 2282–2292, 2001.
3.
SchmollH-J, ArnoldD.: Update on capecitabine in colorectal cancer. Oncologist, 11: 1003–1009, 2006.
4.
O'ShaughnessJ., MilesD., VukeljaS., MoiseyenkoV., AyoubJ.P., CervantesG., FumoleauP., JonesS., LuiW.Y., MauriacL., TwelvesC., Van HazelG., VermaS., LeonardR.: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol, 20: 2812–2823, 2002.
5.
PiergaJ.Y., FumoleauP., BrewerY., ZelekL., MartinD., TurpinF.L., GoudierM.J., Gil-DelgadoM., BaticleJ.L., NamerM., CholletP., SutherlandW., BaratsJ.C., The Cooperative Group of the French capecitabine compassionate use program: Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. Breast Cancer Res Treat, 88: 117–129, 2004.
6.
CunninghamD., ChauI., StockenD., DaviesC., DunnJ., ValleJ., SmithD., StewardW., HarperP., NeoptolemosJ.: Phase III randomized comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer,3(suppl): 4, 2005.
7.
StadlerW.M., HalabiS., RiniB., ErnstoffM.S., DavilaE., PicusJ., BarrierR., SmallE.J., Cancer and Leukemia Group B: A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer, 107: 1273–1279, 2006.
8.
HennessyB.T., GauthierA.M., MichaudL.B., HortobagyiG., ValeroV.: Lower dose capecitabine has a favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at MD Anderson Cancer Center and a rewiew of capecitabine toxicity in the literature. Ann Oncol, 16: 1289–1296, 2005.
